@wc_ratcliff I discuss these issues with respect to cancer evolution here: https://t.co/IjZNcoKV1H, but the same applies in other evolutionary settings as well.
RT @mathoncbro: "Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spuri…
RT @mathoncbro: "Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spuri…
RT @mathoncbro: "Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spuri…
RT @mathoncbro: "Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spuri…
RT @mathoncbro: "Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spuri…
"Comparisons of numerical values of selective advantage without regard for the underlying model and stage can lead to spurious conclusions." Very nice commentary on driver mutations from @IBozic_ https://t.co/oVq9SEjjP8 https://t.co/oHfUF1rlBs
RT @CR_AACR: How big is the selective advantage of cancer drivers? In this #CR_Perspectives Ivana Bozic argues that it is dependent on the…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
Looking forward to reading @IBozic_ !!
RT @CR_AACR: How big is the selective advantage of cancer drivers? In this #CR_Perspectives Ivana Bozic argues that it is dependent on the…
RT @CR_AACR: How big is the selective advantage of cancer drivers? In this #CR_Perspectives Ivana Bozic argues that it is dependent on the…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
RT @CR_AACR: How big is the selective advantage of cancer drivers? In this #CR_Perspectives Ivana Bozic argues that it is dependent on the…
RT @camtflower: In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff m…
In @CR_AACR today- a nice essay highlighting some of the reasons for discrepancy in estimated oncogene advantage b/t diff math models of tumor evolution. https://t.co/1rY8y1C1ro https://t.co/LSTzWjPbN8
How big is the selective advantage of cancer drivers? In this #CR_Perspectives Ivana Bozic argues that it is dependent on the underlying model and stage of cancer evolution that need to be considered to avoid spurious conclusions. https://t.co/kZF617P6UI h
Quantification of the Selective Advantage of Driver Mutations Is Dependent on the Underlying Model and Stage of Tumor Evolution https://t.co/X5tDYaR4uz